Navigation Links
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
Date:6/3/2008

with stage IIb, III or IV non-small

cell lung cancer (NSCLC) unsuitable for radical therapy" (Abstract number

3037):

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF- will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
5. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
8. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Ontotext S4 , The Self ... . Now the same enterprise hardened text mining, ... unstructured data is available to start-ups and mid-size businesses ... Organizations that do not have resources to evaluate and ... S4 since there is no need for on premise ...
(Date:8/21/2014)... August 21, 2014 SoundConnect ... been recognized as one of the nation’s Fastest ... magazine for the 2nd consecutive year. Inc. magazine ... annual Inc. 500|5000, an exclusive ranking of the ... most comprehensive look at the most important segment ...
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax Global, ... located in Raleigh, NC , ... as Vice President of Administration. ... oversee all corporate processes, including their alignment with ... Global, Brad worked as an HR executive, specializing ...
(Date:8/20/2014)... history lessons often have it that American Indians largely ... chicken pox, influenza and tuberculosis brought to the New ... vary, about 20 million people lived in the Americas ... them were killed by European diseases., But new research ... University and Johannes Krause of the University of Tubingen ...
Breaking Biology Technology:Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Clintrax Global, Inc. Announces Addition to Executive Team 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... Calif., April 4, 2011 Ambry Genetics announced today ... (CSP) in Ion Torrent,s new service provider program. Ion ... are trusting with their samples has been trained and ... sequence data. (Logo: http://photos.prnewswire.com/prnh/20110307/LA59848LOGO ) ...
... 4, 2011 Cellectis (Alternext: ALCLS), the genome ... license agreement with a pharmaceutical company covering certain uses of ... oncology therapeutic field. This agreement has triggered an ... Further details of the arrangement have not been disclosed. ...
... NEW YORK and TEL AVIV, Israel, April 4, 2011 ... LLC, and Pronto Diagnostics Ltd, both of which are ... announced that they have entered into a Distribution Agreement ... for Signal,s Myeloma Prognostic Risk Signature (MyPRS) test in ...
Cached Biology Technology:Ambry Genetics is First Authorized Customer Service Provider in New Ion Torrent CSP Program 2Ambry Genetics is First Authorized Customer Service Provider in New Ion Torrent CSP Program 3Signal Genetics and Pronto Diagnostics Announce Distribution Agreement 2
(Date:8/21/2014)... A team of researchers at Louisiana ... for using affordable, consumer-grade 3D printers and ... can contain antibacterial and chemotherapeutic compounds for ... of doctoral students and research faculty from ... programs collaborated to create filament extruders that ...
(Date:8/21/2014)... involves the pancreas digesting itself resulting in severe abdominal ... UK around 20,000 patients are diagnosed with the disease ... and treatment is restricted to intravenous fluid and nutritional ... of Life Sciences, who led the research, said "The ... gall stones and excessive alcohol intake combined with a ...
(Date:8/20/2014)... (HCI) at the University of Utah have identified and ... the unregulated enzyme driving the blood cancer chronic myeloid ... 6,000 new cases of CML will be diagnosed in ... inhibitors (TKIs), target BCR-ABL and are effective at controlling ... it in a way that allows patients to get ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... and the Minneapolis Heart Institute Foundation, in conjunction with ... recently announced two grants from the company totaling more ... and nutrition initiatives for Hearts Beat Back: The Heart ... project with a goal of reducing heart attacks in ...
... Boulder, Colo., USA New Geology papers ... feedbacks; evidence of catastrophic spillover from kilometer-deep bodies of ... ozone depletion; "fingerprinting" San Andreas fault sandstone; a climax ... undergoing continental breakup; garnet as a proxy for subduction ...
... a wide cross-section of human society, both as a common ... well understood is the global nature of this association between ... societies. This relationship is explored by David Wilson of Ecology ... Melbourne in Australia in a paper published in the Springer ...
Cached Biology News:UnitedHealth Group grants more than $1 million for the heart of New Ulm project 2GSA's top geoscience journal posts 9 new articles 2GSA's top geoscience journal posts 9 new articles 3GSA's top geoscience journal posts 9 new articles 4GSA's top geoscience journal posts 9 new articles 5GSA's top geoscience journal posts 9 new articles 6GSA's top geoscience journal posts 9 new articles 7GSA's top geoscience journal posts 9 new articles 8Is the humble fig more than just a fruit? 2
Replacement Parts for Electrophoresis Apparatus...
Histone H2A Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Detects ~14 kDa Histone H2A. It does not cross-react with other Histones. Reacts with human/mouse/rat. Performs w...
...
CMRL Medium-1066 (1X) liquid...
Biology Products: